2005•Journal of Qilu OncologyRequires access
Chemoembolization for hepatocellular carcinoma with portal vein thrombosis
Xiaoming He
Open publisher page 0 citations
Abstract
The objective of this study was to study the clinical effectiveness of arterial chemoembolization for hepatocellular carcinoma with portal vein thrombosis. One hundred and sixteen cases of hepatocellular carcinoma were divided into three growps. Group A (32 cases) were treated with simple chemotherapy, Group B (66 cases) with usual chemoembolization and Group C (18 cases) with segmental or subsegmental arterial chemoembolization. Results: the 6-,12-,18- and 24- month survival rate of Group A were 25.0%(8/32), 9.4%(3/32), 3.1%(1/32) and 0(0/32), respectively. That of Group B were 53.0%(35/66), 25.8%(17/66), 9.1%(6/66) and 3.0%(2/66), respectively. And that of Group C were 72.2%(13/18), 44.4%(8/18), 22.2%(4/18) and 11.1%(2/18), respectively. The disappearance rate of portal vein thrombosis were 3.1%(1/32), 19.7%(13/16) and 44.4%(8/18), respectively. The outcomes were significantly different in the three growps in survival rate, P0.05, and disapearance rate of portal vein thrombosis, P0.01. In conclusion, transcatheter hepatic artery chemoembolization is the choice of treating hepatocellular carcinoma with portal vein thrombosis. It is more effevtive than the simple chemotherapy, especially with segmental or subsegmental arterial chemoembolization.